A phase Ib study combining irinotecan with AZD1775, a selective WEE1 inhibitor, in RAS (KRAS or NRAS) or BRAF mutated metastatic colorectal cancer patients who have progressed on first-line therapy. The gene discussed is BRAF; the disease is metastatic colorectal cancer.